ProteoThera's technology is motivated by the need for potential protein and peptide therapies to be targeted to the tissues where they are needed for activity. Numerous peptides with a short systemic half-life have failed to be effective when tested for local applications because they are not able to stay resident long enough to be therapeutic. Furthermore, for poorly vascularized tissues like the joint cartilage and cornea of the eye, peptides are unable to reach the tissue since they cannot rely on distribution through the blood supply to the target. ProteoThera's technology solves this problem by fusing potential therapies with a 21-amino acid proprietary matrix-binding peptide that allows for extended residence and activity at the site of local application in matrix-rich tissues. ProteoThera is a preclinical biotech with an initial development program focused on fusion of the matrix-binding peptide with the interleukin-1 receptor antagonist, seeking investment and collaborative opportunities.